The biotech industry hasn't performed well this year, even by the standards of the struggling stock market. The SPDR S&P Biotech ETF -- an industry benchmark -- is down by 36% year to date. The good news is that there are still plenty of great biotech stocks that could be solid long-term picks.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting